EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH (EEJPH)

ISSN: 2992-4081 ©EEJPH Publications

Volume 7 Issue 2 2025

Role of the Gut-Prostate Axis in Benign Prostatic Hyperplasia Development

Masika Anna Mahinda

Department of Community Pharmacy Kampala International University Uganda

Email:mahindamasika@studwc.kiu.ac.ug

ABSTRACT

Benign Prostatic Hyperplasia (BPH) is a common condition among aging men, characterized by prostate enlargement and lower urinary tract symptoms (LUTS). Emerging evidence suggests a significant interaction between gut microbiota and prostate health, termed the gut-prostate axis. This review explores the bidirectional relationship between gut microbial composition, systemic inflammation, metabolic alterations, and the pathophysiology of BPH. Key mechanisms such as microbial dysbiosis, metabolite production (e.g., short-chain fatty acids and trimethylamine N-oxide), and immune modulation are examined. The therapeutic potential of modulating gut microbiota through probiotics, prebiotics, and dietary interventions for BPH management is also discussed. A deeper understanding of this axis may pave the way for novel non-invasive therapies for BPH.

Keywords: Gut-prostate axis, benign prostatic hyperplasia, microbiota, inflammation, probiotics, metabolic syndrome

INTRODUCTION

Benign Prostatic Hyperplasia (BPH) is a non-malignant enlargement of the prostate gland that affects aging men. The condition is characterized by the proliferation of stromal and epithelial cells within the prostate, leading to the formation of nodules in the periurethral zone[1, 2]. This growth causes compression of the urethra, resulting in lower urinary tract symptoms (LUTS). The development of BPH is a multifactorial process influenced by hormonal changes, genetic predisposition, and local tissue interactions. Key mechanisms include androgen dependence, inflammation, growth factors and cytokines, and fibroblast growth factor (FGF) and transforming growth factor-beta (TGF-β). BPH is one of the most prevalent conditions in aging males, affecting approximately 50% of men by the age of 60 and up to 90% by the age of 85[3]. Treatment options for BPH range from conservative management to pharmacological and surgical interventions. Alpha-blockers and 5-alpha reductase inhibitors are commonly used to alleviate symptoms and reduce prostate size. Minimally invasive techniques like transurethral resection of the prostate (TURP) and laser therapies are employed for refractory cases. Emerging therapies such as stem cell therapy, targeted biologics, and the role of the gut microbiome are expanding the therapeutic landscape[4, 5]. The gut-organ axes are integrative frameworks that describe the bidirectional communication between the gut and other organ systems. Two of the most extensively studied axes are the gut-liver axis and the gut-brain axis. The gut-liver axis is interconnected via the portal vein, allowing gut-derived metabolites, toxins, and microbial products to directly influence liver function. Disruptions in this axis, such as increased intestinal permeability or dysbiosis, contribute to the pathogenesis of liver diseases, including non-alcoholic fatty liver disease (NAFLD) and cirrhosis[6].

The gut-prostate axis is an emerging concept in urological research that explores the potential relationship between gut microbiota, intestinal health, and prostate diseases such as BPH. Mechanisms linking the gut and prostate include inflammation, hormone modification, and immune system crosstalk[7–9]. Evidence supporting the gut-prostate axis includes distinct gut microbial signatures in patients with BPH compared to healthy individuals, and diet-induced modifications in the gut microbiome have been linked to prostate health. Understanding the gut-prostate axis opens new avenues for the management of BPH, such as supplementing

with beneficial microbes or prebiotic compounds, targeting microbial metabolites as therapeutics, and implementing personalized medicine. By elucidating the interplay between gut microbiota, systemic inflammation, and prostate health, this concept paves the way for innovative, non-invasive therapies that complement existing treatments for BPH.

Pathophysiology of BPH

The pathophysiology of BPH is multifactorial, involving hormonal regulation, inflammatory processes, and systemic factors such as metabolic syndrome and immune dysregulation. Hormonal changes, particularly involving androgens and estrogens, play a pivotal role in the pathogenesis of BPH. Testosterone and Dihydrotestosterone (DHT) are the primary androgen involved in prostate growth, which sustains prostate growth throughout a man's life and becomes dysregulated with age, contributing to excessive tissue proliferation[10, 11]. Estrogens, particularly estradiol, may stimulate estrogen receptor-α (ERα) in the prostate, promoting stromal proliferation and inflammation. Imbalances in the androgen-to-estrogen ratio are hypothesized to disrupt the equilibrium of growth-promoting and growth-inhibiting factors in the prostate[12, 13].

Inflammatory processes in prostate tissue are a critical component of BPH pathophysiology, contributing to tissue remodeling, fibrosis, and hyperplasia. Prostatic inflammation may result from infections, autoimmune responses, or exposure to irritants such as dietary factors, urinary reflux, or hormonal imbalances. Persistent inflammation leads to the recruitment of immune cells, including macrophages, lymphocytes, and neutrophils, to the prostate tissue. Inflammatory cells release pro-inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor-α (TNF-α), which stimulate stromal cell proliferation, promote extracellular matrix remodeling, and induce oxidative stress, damaging epithelial and stromal cells and triggering compensatory hyperplasia[14, 15].

Systemic metabolic and immune dysregulation significantly influence the development and progression of BPH. Components of metabolic syndrome, such as obesity, insulin resistance, dyslipidemia, and hypertension, are associated with increased BPH risk. Adipose tissue secretes inflammatory cytokines, such as leptin and adiponectin, which contribute to systemic and prostatic inflammation. Insulin resistance elevates levels of insulin-like growth factor-1 (IGF-1), promoting prostate stromal and epithelial cell proliferation. Obesity leads to increased aromatase activity, raising systemic estrogen levels and disrupting the androgen-estrogen balance. Dyslipidemia alters lipid metabolism within the prostate, inducing oxidative stress and inflammation. A comprehensive understanding of these mechanisms is essential for developing targeted therapies to manage BPH effectively[16].

The Gut Microbiota and Systemic Health

The gut microbiota is a complex ecosystem of trillions of microorganisms, including bacteria, viruses, fungi, archaea, and protozoa, which live symbiotically within the gastrointestinal (GI) tract. It plays a pivotal role in metabolic processes, immune system regulation, and disease prevention. Dysbiosis of gut microbiota, which refers to an imbalance in its composition, has been linked to a wide range of systemic health conditions, including obesity, type 2 diabetes, cardiovascular diseases, inflammatory bowel diseases, and neurodegenerative disorders. The gut microbiota is predominantly composed of bacteria, with the largest diversity found in the colon[17]. The major bacterial phyla in the human gut include Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria. These microbes form a delicate balance, with a variety of species fulfilling different roles in host metabolism, immune regulation, and nutrient absorption. The gut microbiota is essential for digesting food components that the host cannot metabolize, such as complex carbohydrates and fibers[18]. Microbial enzymes break down these compounds, producing short-chain fatty acids (SCFAs) like acetate, propionate, and butyrate, which serve as energy sources for colonocytes and help maintain intestinal homeostasis. Gut bacteria also influence lipid metabolism, amino acid metabolism, and bile acid metabolism. For instance, certain gut microbiota can convert primary bile acids into secondary bile acids, which regulate fat digestion and cholesterol homeostasis.[19]

Dysbiosis is crucial for the development and maintenance of the immune system. It interacts with immune cells in the intestinal mucosa to modulate systemic immunity. Beneficial microbes help educate the immune system, promoting tolerance to harmless antigens and supporting the defense against pathogens. The gut microbiota is involved in the regulation of mucosal immunity, maintaining the intestinal barrier integrity, and preventing pathogen invasion. Barrier function and protection are maintained by the intestinal epithelial cells, which are lined by a mucus layer maintained by beneficial gut microbes. This layer acts as a barrier against pathogens and toxins, limiting the infiltration of harmful microorganisms into systemic circulation. Gut microbiota also help produce antimicrobial peptides that protect the intestine from infection and contribute to the maintenance of gut health[20].

Dysbiosis refers to the disruption of the normal microbial community in the gut, which can arise from factors such as poor diet, infections, stress, antibiotics, and environmental toxins. Dysbiosis can lead to chronic low-grade inflammation, which plays a role in various diseases, including metabolic disorders, cardiovascular diseases, autoimmune diseases, and neurodegenerative conditions[20]. Three key metabolites produced by the

gut microbiota have systemic effects on host health: short-chain fatty acids (SCFAs), lipopolysaccharides (LPS), and trimethylamine N-oxide (TMAO). SCFAs, primarily acetate, propionate, and butyrate, are produced by the fermentation of fiber and resistant starch by gut bacteria. LPS, components of the outer membrane of Gram-negative bacteria, are potent endotoxins. Under conditions of dysbiosis, elevated levels of LPS in the gut can translocate into the bloodstream, triggering an inflammatory response. Trimethylamine N-Oxide (TMAO) is a metabolite produced by the liver from trimethylamine (TMA), generated by gut microbiota from choline, phosphatidylcholine, and L-carnitine, all of which are found in animal-based foods. Elevated levels of TMAO have been implicated in the pathogenesis of cardiovascular diseases, as it promotes cholesterol deposition in arterial walls, impairs endothelial function, and enhances platelet aggregation[21]. Understanding the complex interplay between gut microbiota and systemic health offers potential therapeutic avenues for the prevention and treatment of a wide range of chronic diseases.

The Gut-Prostate Axis: Mechanisms of Interaction

The Gut-Prostate Axis: Mechanisms of Interaction

The gut-prostate axis is an emerging concept in the field of microbiome research that highlights the intricate interaction between the gut microbiota and prostate health. Emerging evidence suggests that the gut microbiome, through various molecular and immunological pathways, plays a critical role in regulating prostate function, inflammation, and even the development of prostate diseases, including benign prostatic hyperplasia (BPH) and prostate cancer (PCa). The gut-prostate axis is mediated by microbial dysbiosis, the production of metabolites, and immune modulation, each influencing prostate tissue through systemic and local mechanisms[22].

Microbial Dysbiosis and Prostate Inflammation

Microbial dysbiosis, a condition where there is an imbalance in the gut microbiota, has been linked to a range of inflammatory diseases, including prostate inflammation. The gut microbiota is involved in maintaining immune homeostasis, and any disruption can lead to systemic inflammation that impacts various organs, including the prostate. Dysbiosis has been shown to induce an inflammatory cascade in the prostate tissue through the activation of immune pathways, resulting in a chronic state of low-grade inflammation, a hallmark of many prostate disorders, including benign prostatic hyperplasia and prostate cancer[23].

Link between gut microbiota and local prostate inflammation: The interaction between gut microbiota and prostate inflammation is thought to occur through several pathways. Dysbiosis can lead to the translocation of microbial products, such as lipopolysaccharides (LPS), into the systemic circulation. These products can activate the immune system, resulting in the recruitment of pro-inflammatory cytokines and immune cells to the prostate. Additionally, certain bacterial species may produce metabolites that directly influence the prostate microenvironment, promoting an inflammatory response. The imbalance in the gut microbiota can also alter the production of sex hormones and other mediators that affect prostate health[24, 25].

Evidence from animal models and human studies: Animal models have provided substantial evidence linking gut microbiota dysbiosis with prostate inflammation. Studies have demonstrated that animals subjected to antibiotics (which disrupt their gut microbiota) show reduced prostate inflammation and altered immune responses. Moreover, animal models of prostate cancer have shown that the presence or absence of specific gut bacteria can modulate the development and progression of the disease, further supporting the notion of a gut-prostate interaction[25]. Human studies have also observed an association between gut microbiota composition and prostate diseases. For instance, men with chronic prostatitis or BPH have been found to exhibit altered gut microbiota profiles compared to healthy controls. Furthermore, patients with prostate cancer have been shown to have a significantly different gut microbiota composition, which may influence the progression of the disease[26].

Metabolites and Hormonal Regulation

The gut microbiota produces a wide array of metabolites that can influence host physiology, including the regulation of hormones that play a crucial role in prostate function. Short-chain fatty acids (SCFAs), trimethylamine-N-oxide (TMAO), and lipopolysaccharides (LPS) are among the key metabolites produced by gut bacteria that can affect hormonal pathways and prostate health[27].

Impact of SCFAs, TMAO, and LPS on hormonal pathways:

i. **Short-Chain Fatty Acids (SCFAs):** SCFAs, including acetate, propionate, and butyrate, are the byproducts of microbial fermentation of dietary fibers. These metabolites are known to have various systemic effects, including modulating inflammation and immune responses. SCFAs can influence prostate health by regulating the levels of androgens, such as testosterone and dihydrotestosterone (DHT), which are pivotal in the development and progression of prostate disorders. SCFAs have been shown to enhance the production of anti-inflammatory cytokines and suppress the pro-inflammatory cytokines in the prostate, potentially mitigating prostate inflammation and lowering the risk of prostate cancer[28].

ii. **Trimethylamine-N-oxide (TMAO):** TMAO is a metabolite produced by the gut microbiota during the digestion of foods rich in choline and carnitine, such as red meat and eggs. TMAO has been

implicated in cardiovascular diseases, but recent studies have suggested that it may also influence prostate cancer progression. TMAO can modulate the levels of testosterone and its active form, DHT, which are critical in prostate cellular proliferation and androgen receptor signaling, pathways involved in prostate cancer development[29].

iii. **Lipopolysaccharides (LPS):** LPS is a component of the outer membrane of Gram-negative bacteria that, when translocated into the bloodstream, can induce systemic inflammation. Elevated LPS levels have been associated with chronic low-grade inflammation, which is a risk factor for prostate diseases. LPS can activate various inflammatory cytokines that influence androgen signaling in the prostate, potentially leading to prostate growth and the development of malignancy[30].

Immune Modulation

The immune system is another critical link between the gut microbiota and prostate health. The gut is home to a significant portion of the body's immune cells, and the gut microbiota plays a pivotal role in shaping immune responses. Dysbiosis can alter the composition and function of gut-derived immune cells, which can then influence prostate tissue through the release of immune mediators[31].

Gut-derived immune cells and cytokines influencing prostate tissue: Gut-associated lymphoid tissue (GALT) plays a central role in regulating the immune system. When the gut microbiota is disrupted, there is often an increase in pro-inflammatory cytokines and immune cells that can migrate from the gut to distant tissues, including the prostate. These cells can influence the prostate microenvironment by secreting cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β), all of which are implicated in prostate inflammation and carcinogenesis[32].

Moreover, the presence of certain microbial species in the gut can influence the differentiation of T-helper cells (Th17 cells), which are involved in pro-inflammatory responses. These immune cells can affect prostate tissue by modulating the local immune environment, potentially promoting chronic inflammation and fostering an environment conducive to the development of prostate diseases, including cancer. In addition to T-helper cells, regulatory T cells (Tregs), which are important for immune tolerance and preventing excessive inflammation, can be influenced by the gut microbiota. A healthy microbiome may promote the development of Tregs, which in turn can help maintain immune balance in the prostate and prevent pathological inflammation.

The gut-prostate axis is a complex and multifaceted interaction that involves microbial dysbiosis, the production of metabolites, and immune modulation[32]. Dysbiosis has been linked to prostate inflammation, while microbial metabolites such as SCFAs, TMAO, and LPS play crucial roles in regulating prostate hormone pathways and influencing immune responses. Disruptions in the gut microbiota can alter these processes, contributing to the development of various prostate diseases, including benign prostatic hyperplasia and prostate cancer. A better understanding of the mechanisms underlying the gut-prostate axis offers the potential for novel therapeutic approaches targeting the microbiome to prevent or treat prostate diseases.

Evidence Supporting the Gut-Prostate Axis in BPH

Animal models have provided valuable insights into the role of gut microbiota in prostate health and the development of BPH.

Germ-Free Mouse Models: Germ-free mice, which are raised without any gut microbiota, have been used to study the impact of the microbiome on prostate health. These models often exhibit altered immune responses and metabolic functions that could mimic some aspects of BPH. A study by Chen et al. [33] demonstrated that colonization of germ-free mice with specific microbiota from BPH patients led to an increase in prostate size and inflammation, supporting the hypothesis that gut microbes can influence prostate health. Furthermore, germ-free mice exhibited lower levels of inflammation and prostate enlargement when compared to conventional mice, suggesting that gut microbiota may be crucial in mediating prostate enlargement via inflammatory pathways.

Microbiota-Targeted Interventions in Animal Models: Research has shown that modulation of the gut microbiome through dietary changes, probiotics, or antibiotics can influence prostate health outcomes in animal models. For instance, supplementation with probiotics has been found to reduce prostatic inflammation and prevent the enlargement of the prostate in rodent models of BPH. A study by Yadav et al. [34] demonstrated that administration of *Lactobacillus* and *Bifidobacterium* strains in rats with experimentally induced BPH led to reduced prostate weight and lower expression of pro-inflammatory cytokines such as TNF-α and IL-6.

Antibiotic-Induced Gut Microbial Disruption and Prostate Enlargement: In rodent studies, the administration of antibiotics that disrupt the gut microbiome has been shown to exacerbate prostate enlargement and inflammation. In particular, the depletion of *Lactobacillus* and *Bifidobacterium* populations through antibiotics was associated with an increase in prostate size and exacerbation of BPH symptoms[35]. This suggests that maintaining a balanced gut microbiome may have protective effects against BPH development.

Gut Microbiota and Immune Response in BPH Models: Animal studies have also explored how gut microbiota modulates immune responses that may influence prostate health. The gut microbiota is known to shape the immune system by interacting with the gut-associated lymphoid tissue (GALT), which in turn affects systemic inflammation. In animal models of BPH, it has been observed that the modulation of gut microbiota

can influence immune cell activation and cytokine production, which may impact prostate tissue remodeling and enlargement. The role of immune-mediated inflammation in BPH is well-established, and studies suggest that gut microbiota may act as a modulator of this inflammatory response[36].

The growing body of evidence supporting the gut-prostate axis in BPH highlights the intricate relationship between gut microbiota and prostate health. Clinical studies have shown that gut dysbiosis is associated with BPH severity, particularly through mechanisms involving inflammation and hormonal regulation. Furthermore, animal studies have demonstrated that microbial modulation can influence prostate enlargement and inflammation, providing a potential therapeutic avenue for managing BPH[37]. However, while these findings are promising, further research, including human clinical trials, is needed to fully understand the mechanisms underlying the gut-prostate axis and its potential as a target for BPH prevention and treatment.

Therapeutic Implications

Prostate health is critical to aging men, with benign prostatic hyperplasia (BPH) being one of the most prevalent conditions. In recent years, the role of the gut microbiota in modulating prostate health has gained significant attention. The intricate relationship between the gut microbiota, inflammation, and prostate diseases opens up new therapeutic avenues, including the use of probiotics, prebiotics, dietary interventions, fecal microbiota transplantation (FMT), and pharmacological approaches targeting microbial metabolites. This section explores these therapeutic strategies comprehensively.

Probiotics and Prebiotics

Probiotics and prebiotics represent a promising area of research in the management of prostate health, particularly for conditions like BPH. Both are involved in maintaining a healthy gut microbiota, which in turn can influence systemic inflammation and prostate health.

Effects on Gut Microbiota Composition and Systemic Inflammation

The gut microbiota plays a significant role in modulating systemic inflammation. Dysbiosis, or the imbalance in gut microbiota composition, has been linked to various inflammatory conditions, including BPH. The use of probiotics, which are live microorganisms that confer health benefits to the host when consumed in adequate amounts, can help restore the balance of gut bacteria. By promoting the growth of beneficial bacteria like *Lactobacillus* and *Bifidobacterium*, probiotics help reduce the overgrowth of harmful bacteria and subsequently lower systemic inflammation. This can have a beneficial impact on prostate health, as chronic inflammation is a known contributor to the pathogenesis of BPH[38].

Prebiotics, on the other hand, are non-digestible food components, typically fibers and oligosaccharides, that selectively stimulate the growth and activity of beneficial gut microbes. Prebiotics work synergistically with probiotics to enhance their effects by nourishing the beneficial microbes, thereby contributing to a more balanced gut microbiota composition. This balance plays a role in regulating immune responses and lowering inflammation, which can be particularly beneficial in conditions like BPH where inflammation is a key pathological feature.

Studies on Specific Strains Relevant to BPH

Studies have identified specific probiotic strains that could have therapeutic benefits in BPH. *Lactobacillus* strains, particularly *L. acidophilus* and *L. rhamnosus*, have shown potential in modulating inflammatory cytokines that may reduce prostate enlargement. Similarly, *Bifidobacterium* species are also being explored for their ability to modulate immune responses. Some studies suggest that these strains might help alleviate lower urinary tract symptoms associated with BPH, likely through their anti-inflammatory properties[39, 40].

Additionally, *Lactobacillus reuteri* has been found to influence the production of testosterone, a hormone implicated in prostate enlargement. The modulation of hormonal levels by probiotics may thus offer a non-invasive therapeutic strategy for managing BPH.

Dietary Interventions

Dietary modifications have long been a cornerstone of managing prostate health. The composition of the diet can influence gut microbiota, modulate inflammation, and affect prostate tissue metabolism. Key dietary components, such as fiber, fermented foods, and polyphenols, have shown significant promise in this context.

Role of Fiber, Fermented Foods, and Dietary Polyphenols

Dietary fiber, abundant in fruits, vegetables, and whole grains, is crucial for maintaining gut health. It acts as a substrate for beneficial gut bacteria, promoting the production of short-chain fatty acids (SCFAs) like butyrate, which have anti-inflammatory effects. Increased fiber intake is associated with improved gut microbiota composition and a reduction in markers of systemic inflammation, which may directly influence prostate health[41]. Fermented foods such as yogurt, kefir, and kimchi contain beneficial microorganisms that act as natural probiotics. These foods can improve gut health, enhance the immune response, and potentially alleviate symptoms of BPH. Studies have shown that fermented foods help regulate gut dysbiosis, reducing inflammation, and improving the gut-brain-prostate axis. Polyphenols, found in foods such as berries, green tea, and cruciferous vegetables, possess anti-inflammatory, antioxidant, and anti-cancer properties. These compounds are also known to have a positive effect on the gut microbiota, favoring the growth of beneficial bacteria while inhibiting harmful microbes. In the context of BPH, polyphenols may reduce inflammation in prostate tissues

and slow the progression of prostate enlargement. Notably, resveratrol, a polyphenol found in grapes and red wine, has been linked to reduced prostate size and improved prostate function.

Fecal Microbiota Transplantation (FMT)

Fecal microbiota transplantation (FMT), the process of transferring stool from a healthy donor to a recipient, has emerged as a novel therapeutic approach in various gastrointestinal and systemic diseases. Although still in the early stages of exploration for prostate health, FMT represents a potentially powerful tool for restoring a balanced gut microbiome, which could have a downstream impact on inflammation and prostate health [42].

Emerging Insights and Potential Applications

FMT has been widely studied in the context of gut diseases, particularly Clostridium difficile infection. More recently, studies have suggested that FMT could be beneficial in managing chronic inflammatory diseases, such as BPH. By replenishing the gut microbiota with healthy, diverse microbial populations, FMT may help reduce gut-related inflammation that contributes to prostate enlargement. Additionally, FMT may modulate systemic immune responses, impacting prostate tissue inflammation and potentially slowing the progression of BPH [43]. As FMT involves transferring microbial communities from a donor, it holds promise as a means of reprogramming the recipient's immune system, potentially modulating the local immune environment in the prostate. However, extensive clinical trials and safety studies are needed to assess the efficacy and safety of FMT in prostate diseases.

Pharmacological Approaches: Pharmacological interventions targeting microbial metabolites are an emerging frontier in prostate health management. The metabolites produced by gut bacteria, such as SCFAs, bile acids, and tryptophan derivatives, play crucial roles in regulating immune responses and inflammation.

Targeting Microbial Metabolites to Modulate Prostate Health: Pharmacological approaches to modulating microbial metabolites involve using drugs or dietary interventions that influence gut microbiota composition or enhance the production of beneficial metabolites. For instance, SCFAs like butyrate, propionate, and acetate, produced by gut bacteria during the fermentation of fiber, are known to have anti-inflammatory effects. Butyrate, in particular, has been shown to suppress pro-inflammatory cytokine production and reduce oxidative stress in various tissues, including the prostate. Strategies to increase SCFA production or administer SCFA analogs could hold promise in treating BPH.

Moreover, bile acids, which are produced in the liver and modified by gut bacteria, play a role in regulating inflammation and immune responses. Certain pharmaceutical agents that influence the bile acid pool or their receptors may also offer therapeutic potential for BPH by modulating gut inflammation and immune activation. Finally, microbial metabolites derived from tryptophan, such as indole and its derivatives, have been implicated in modulating the immune system and reducing inflammation. Targeting the microbial pathways that produce these metabolites could provide an innovative pharmacological strategy for managing prostate health, especially in conditions characterized by chronic inflammation like BPH.

CONCLUSION

The therapeutic implications of gut microbiota modulation in prostate health are vast and multifaceted. Probiotics and prebiotics offer promising avenues for restoring gut microbiota balance and reducing inflammation, with certain strains showing potential in alleviating BPH symptoms. Dietary interventions, including fiber, fermented foods, and polyphenols, further enhance gut health and reduce systemic inflammation, contributing to better prostate function. FMT, although still emerging, holds potential as a revolutionary treatment for restoring microbial balance and reducing inflammation in prostate diseases. Pharmacological approaches targeting microbial metabolites, such as SCFAs and bile acids, represent another exciting frontier in managing prostate health. Collectively, these strategies offer a holistic approach to prostate disease management, with a focus on modulating the gut-prostate axis to reduce inflammation and promote prostate health. Further research and clinical trials will be crucial to fully understand their therapeutic potential.

REFERENCES

1. Ibiam, U.A., Uti, D.E., Ejeogo, C.C., Orji, O.U., Aja, P.M., Nwamaka, E.N., Alum, E.U., Chukwu, C., Aloke, C., Chinedum, K.E., Agu, P., Nwobodo, V.: In Vivo and in Silico Assessment of Ameliorative Effects of Xylopia aethiopica on Testosterone Propionate-Induced Benign Prostatic Hyperplasia. Pharmaceutical Fronts. 05, e64–e76 (2023). https://doi.org/10.1055/s-0043-1768477
2. Schauer, I.G., Rowley, D.R.: The Functional Role of Reactive Stroma in Benign Prostatic Hyperplasia. Differentiation. 82, 200–210 (2011). https://doi.org/10.1016/j.diff.2011.05.007
3. Ibiam, U.A., Uti, D.E., Ejeogo, C.C., Orji, O.U., Aja, P.M., Nwamaka, E.N., Alum, E.U., Chukwu, C., Aloke, C., Itodo, M.O., Agada, S.A., Umoru, G.U., Obeten, U.N., Nwobodo, V.O.G., Nwadum, S.K., Udoudoh, M.P.: Xylopia aethiopica Attenuates Oxidative Stress and Hepatorenal Damage in Testosterone Propionate-Induced Benign Prostatic Hyperplasia in Rats. Journal of Health and Allied Sciences NU. 14, 477–485 (2024). https://doi.org/10.1055/s-0043-1777836
4. Miernik, A., Gratzke, C.: Current Treatment for Benign Prostatic Hyperplasia. Dtsch Arztebl Int. 117, 843–854 (2020). https://doi.org/10.3238/arztebl.2020.0843

5. Lokeshwar, S.D., Harper, B.T., Webb, E., Jordan, A., Dykes, T.A., Neal, D.E., Terris, M.K., Klaassen, Z.: Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol. 8, 529–539 (2019). https://doi.org/10.21037/tau.2019.10.01
6. Albillos, A., de Gottardi, A., Rescigno, M.: The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 72, 558–577 (2020). https://doi.org/10.1016/j.jhep.2019.10.003
7. Brandl, K., Kumar, V., Eckmann, L.: Gut-liver axis at the frontier of host-microbial interactions. Am J Physiol Gastrointest Liver Physiol. 312, G413–G419 (2017). https://doi.org/10.1152/ajpgi.00361.2016
8. Singh, T.P., Kadyan, S., Devi, H., Park, G., Nagpal, R.: Gut microbiome as a therapeutic target for liver diseases. Life Sciences. 322, 121685 (2023). https://doi.org/10.1016/j.lfs.2023.121685
9. Singh, S., Kriti, M., Catanzaro, R., Marotta, F., Malvi, M., Jain, A., Verma, V., Nagpal, R., Tiwari, R., Kumar, M.: Deciphering the Gut–Liver Axis: A Comprehensive Scientific Review of Non-Alcoholic Fatty Liver Disease. Livers. 4, 435–454 (2024). https://doi.org/10.3390/livers4030032
10. Fu, X., Wang, Y., Lu, Y., Liu, J., Li, H.: Association between metabolic syndrome and benign prostatic hyperplasia: The underlying molecular connection. Life Sciences. 358, 123192 (2024). https://doi.org/10.1016/j.lfs.2024.123192
11. Nicholson, T.M., Ricke, W.A.: Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation. 82, 184–199 (2011). https://doi.org/10.1016/j.diff.2011.04.006
12. Chen, B., Cao, D., Chen, Z., Huang, Y., Lin, T., Ai, J., Liu, L., Wei, Q.: Estrogen regulates the proliferation and inflammatory expression of primary stromal cell in benign prostatic hyperplasia. Translational Andrology and Urology. 9, 32231–32331 (2020). https://doi.org/10.21037/tau.2020.02.08
13. Belluti, S., Imbriano, C., Casarini, L.: Nuclear Estrogen Receptors in Prostate Cancer: From Genes to Function. Cancers. 15, 4653 (2023). https://doi.org/10.3390/cancers15184653
14. Meng, Y., Yu, W., Liu, Z., Zhang, M., Chen, Y., Li, S., Fan, Y., Hu, S., Zhang, K., Zhang, Q., Jin, J.: The inflammation patterns of different inflammatory cells in histological structures of hyperplasic prostatic tissues. Translational Andrology and Urology. 9, 1639649–1631649 (2020). https://doi.org/10.21037/tau-20-448
15. Oseni, S.O., Naar, C., Pavlović, M., Asghar, W., Hartmann, J.X., Fields, G.B., Esiobu, N., Kumi-Diaka, J.: The Molecular Basis and Clinical Consequences of Chronic Inflammation in Prostatic Diseases: Prostatitis, Benign Prostatic Hyperplasia, and Prostate Cancer. Cancers. 15, 3110 (2023). https://doi.org/10.3390/cancers15123110
16. Cao, D., Sun, R., Peng, L., Li, J., Huang, Y., Chen, Z., Chen, B., Li, J., Ai, J., Yang, L., Liu, L., Wei, Q.: Immune Cell Proinflammatory Microenvironment and Androgen-Related Metabolic Regulation During Benign Prostatic Hyperplasia in Aging. Front. Immunol. 13, (2022). https://doi.org/10.3389/fimmu.2022.842008
17. Thursby, E., Juge, N.: Introduction to the human gut microbiota. Biochem J. 474, 1823–1836 (2017). https://doi.org/10.1042/BCJ20160510
18. Garcia-Bonete, M.J., Rajan, A., Suriano, F., Layunta, E.: The Underrated Gut Microbiota Helminths, Bacteriophages, Fungi, and Archaea. Life. 13, 1765 (2023). https://doi.org/10.3390/life13081765
19. Kho, Z.Y., Lal, S.K.: The Human Gut Microbiome – A Potential Controller of Wellness and Disease. Front. Microbiol. 9, (2018). https://doi.org/10.3389/fmicb.2018.01835
20. Yoo, J.Y., Groer, M., Dutra, S.V.O., Sarkar, A., McSkimming, D.I.: Gut Microbiota and Immune System Interactions. Microorganisms. 8, 1587 (2020). https://doi.org/10.3390/microorganisms8101587
21. Fakharian, F., Thirugnanam, S., Welsh, D.A., Kim, W.-K., Rappaport, J., Bittinger, K., Rout, N.: The Role of Gut Dysbiosis in the Loss of Intestinal Immune Cell Functions and Viral Pathogenesis. Microorganisms. 11, 1849 (2023). https://doi.org/10.3390/microorganisms11071849
22. Fujita, K., Matsushita, M., De Velasco, M.A., Hatano, K., Minami, T., Nonomura, N., Uemura, H.: The Gut-Prostate Axis: A New Perspective of Prostate Cancer Biology through the Gut Microbiome. Cancers (Basel). 15, 1375 (2023). https://doi.org/10.3390/cancers15051375
23. Matsushita, M., Fujita, K., Hatano, K., De Velasco, M.A., Tsujimura, A., Uemura, H., Nonomura, N.: Emerging Relationship between the Gut Microbiome and Prostate Cancer. World J Mens Health. 41, 759–768 (2023). https://doi.org/10.5534/wjmh.220202
24. Liu, X., Dong, Q.: Associations between gut microbiota and three prostate diseases: a bidirectional two-sample Mendelian randomization study. Sci Rep. 14, 4019 (2024). https://doi.org/10.1038/s41598-024-54293-5
25. Miyake, M., Tatsumi, Y., Ohnishi, K., Fujii, T., Nakai, Y., Tanaka, N., Fujimoto, K.: Prostate diseases and microbiome in the prostate, gut, and urine. Prostate Int. 10, 96–107 (2022). https://doi.org/10.1016/j.prnil.2022.03.004
26. Xu, H., Zhang, Y., Zhang, Y., Shen, C., Zhang, Z., Wang, J., Zhou, D., Wu, Z., Qie, Y., Liu, S., Tian, D., Hu, H., Wu, C.: Causal associations between gut microbiota and chronic prostatitis/chronic pelvic pain

syndrome: a two-sample Mendelian randomization study. Egyptian Journal of Medical Human Genetics. 25, 68 (2024). https://doi.org/10.1186/s43042-024-00540-3
27. Liu, J., Tan, Y., Cheng, H., Zhang, D., Feng, W., Peng, C.: Functions of Gut Microbiota Metabolites, Current Status and Future Perspectives. Aging Dis. 13, 1106–1126 (2022). https://doi.org/10.14336/AD.2022.0104
28. Facchin, S., Bertin, L., Bonazzi, E., Lorenzon, G., De Barba, C., Barberio, B., Zingone, F., Maniero, D., Scarpa, M., Ruffolo, C., Angriman, I., Savarino, E.V.: Short-Chain Fatty Acids and Human Health: From Metabolic Pathways to Current Therapeutic Implications. Life (Basel). 14, 559 (2024). https://doi.org/10.3390/life14050559
29. Zhen, J., Zhou, Z., He, M., Han, H.-X., Lv, E.-H., Wen, P.-B., Liu, X., Wang, Y.-T., Cai, X.-C., Tian, J.-Q., Zhang, M.-Y., Xiao, L., Kang, X.-X.: The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases. Front Endocrinol (Lausanne). 14, 1085041 (2023). https://doi.org/10.3389/fendo.2023.1085041
30. Page, M.J., Kell, D.B., Pretorius, E.: The Role of Lipopolysaccharide-Induced Cell Signalling in Chronic Inflammation. Chronic Stress (Thousand Oaks). 6, 24705470221076390 (2022). https://doi.org/10.1177/24705470221076390
31. Wu, H.-J., Wu, E.: The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes. 3, 4–14 (2012). https://doi.org/10.4161/gmic.19320
32. Bemark, M., Pitcher, M.J., Dionisi, C., Spencer, J.: Gut-associated lymphoid tissue: a microbiota-driven hub of B cell immunity. Trends in Immunology. 45, 211 (2024). https://doi.org/10.1016/j.it.2024.01.006
33. Chen, J., Chen, B., Lin, B., Huang, Y., Li, J., Li, J., Chen, Z., Wang, P., Ran, B., Yang, J., Huang, H., Liu, L., Wei, Q., Ai, J., Cao, D.: The role of gut microbiota in prostate inflammation and benign prostatic hyperplasia and its therapeutic implications. Heliyon. 10, e38302 (2024). https://doi.org/10.1016/j.heliyon.2024.e38302
34. Yadav, A., Kaushik, M., Tiwari, P., Dada, R.: From microbes to medicine: harnessing the gut microbiota to combat prostate cancer. Microb Cell. 11, 187–197. https://doi.org/10.15698/mic2024.05.824
35. Dahiya, D., Nigam, P.S.: Antibiotic-Therapy-Induced Gut Dysbiosis Affecting Gut Microbiota—Brain Axis and Cognition: Restoration by Intake of Probiotics and Synbiotics. Int J Mol Sci. 24, 3074 (2023). https://doi.org/10.3390/ijms24043074
36. Green, G.B.H., Cox-Holmes, A.N., Potier, A.C.E., Marlow, G.H., McFarland, B.C.: Modulation of the Immune Environment in Glioblastoma by the Gut Microbiota. Biomedicines. 12, 2429 (2024). https://doi.org/10.3390/biomedicines12112429
37. Li, Z., Xiong, W., Liang, Z., Wang, J., Zeng, Z., Kołat, D., Li, X., Zhou, D., Xu, X., Zhao, L.: Critical role of the gut microbiota in immune responses and cancer immunotherapy. Journal of Hematology & Oncology. 17, 33 (2024). https://doi.org/10.1186/s13045-024-01541-w
38. Hrncir, T.: Gut Microbiota Dysbiosis: Triggers, Consequences, Diagnostic and Therapeutic Options. Microorganisms. 10, 578 (2022). https://doi.org/10.3390/microorganisms10030578
39. Shah, A.B., Baiseitova, A., Zahoor, M., Ahmad, I., Ikram, M., Bakhsh, A., Shah, M.A., Ali, I., Idress, M., Ullah, R., Nasr, F.A., Al-Zharani, M.: Probiotic significance of Lactobacillus strains: a comprehensive review on health impacts, research gaps, and future prospects. Gut Microbes. 16, 2431643. https://doi.org/10.1080/19490976.2024.2431643
40. Murzilli, S., Mirone, V., Micheletto, M., Tedesco, E., Maira, G.D., Benetti, F., Vanelli, A.: Evaluation of the Immunomodulatory Effects of a Probiotics and Natural Extract-Based Formulation in Bacterial-Induced Prostatitis. Life (Basel). 13, 389 (2023). https://doi.org/10.3390/life13020389
41. Cronin, P., Joyce, S.A., O'Toole, P.W., O'Connor, E.M.: Dietary Fibre Modulates the Gut Microbiota. Nutrients. 13, 1655 (2021). https://doi.org/10.3390/nu13051655
42. Yang, Y., An, Y., Dong, Y., Chu, Q., Wei, J., Wang, B., Cao, H.: Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy. eBioMedicine. 100, 104967 (2024). https://doi.org/10.1016/j.ebiom.2024.104967
43. Yadegar, A., Pakpoor, S., Ibrahim, F.F., Nabavi-Rad, A., Cook, L., Walter, J., Seekatz, A.M., Wong, K., Monaghan, T.M., Kao, D.: Beneficial effects of fecal microbiota transplantation in recurrent Clostridioides difficile infection. Cell Host Microbe. 31, 695–711 (2023). https://doi.org/10.1016/j.chom.2023.03.019

CITE AS: Masika Anna Mahinda (2024). Role of the Gut-Prostate Axis in Benign Prostatic Hyperplasia Development. EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH, 7(2):87-94.